Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | PNMT | P11086 | 9/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015985 | 0.81 | ACHE (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL874814 | 0.80 | ANPEP (0.43) | — | |
| Hydrochloric Acid SCHEMBL584893 | 0.78 | ANPEP (0.45) | — | |
| SCHEMBL16395308 | 0.76 | HTR2C (0.45) | HTR2C | |
| SCHEMBL16395441 | 0.76 | HTR2C (0.45) | HTR2C | |
| SCHEMBL1151104 | 0.76 | HTR2C (0.45) | HTR2C | |
| SCHEMBL23841366 | 0.72 | HTR2A (0.45) | HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL19827770 | 0.72 | HTR2C (0.35) | HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL19829933 | 0.72 | HTR2C (0.35) | HTR2AHTR2CHTR2BPNMT | |
| SCHEMBL19829939 | 0.72 | HTR2C (0.35) | HTR2AHTR2CHTR2BPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4096173-A | Chlorinated 1-aminoindane N-methyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 1978-06-20 | — | — | US | claimed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-4096173-A | Chlorinated 1-aminoindane N-methyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4096173-A | Chlorinated 1-aminoindane N-methyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | HTR2A 465/4885HTR2C 263/4885HTR2B 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.